REMINDER: Department of Infection, Immunity & Cardiovascular Disease Seminar – Thursday 27th September 2018

Title:  “Fishing for clues into the causes of osteoarthritis”
Speaker:  Dr Chrissy Hammond, University of Bristol.
Venue: Lecture Theatre 3, F Floor Medical School.
Time:  12noon – 1:00pm
Abstract: The painful, degenerative, joint condition osteoarthritis affects millions of people in the UK and worldwide. While we know that genes, loading and environmental factors play a role in susceptibility we still don’t fully understand how these come together to cause the condition. Our lab uses zebrafish to try and unpick how genes and load affect the various cells of the joint during development and disease.

For enquiries, please contact:


Date: Friday 26th October 2018
Title:  “Molecular Genetic Advances in the Diagnosis and Care of Inherited Bleeding Disorders”
Speaker:  Professor David Lillicrap, Queen’s University, Ontario, Canada.
Venue:  Lecture Theatre 2, B Floor Medical School.
Time:  4:30pm – 5:30pm
Abstract:  The cloning and characterisation of the genes for the common inherited bleeding disorders in the mid-1980s represented one of the initial examples of the translational impact of molecular biology on clinical medicine. Within a short period of time, the original genetic knowledge was being applied to molecular diagnostic strategies for these disorders and soon after, the first generation of recombinant clotting factors became available. The genes encoding FVIII, FIX and von Willebrand factor are now some of the most extensively studied sequences in the human genome, with a detailed documentation of the types and patterns of sequence variants that result in defective hemostasis. Paralleling these discoveries, the development of novel bioengineered clotting factor concentrates has continued for the past two decades and has now resulted in FVIII and FIX products that exhibit significant extensions to their circulating half-lives. Most recently, following several decades of variable success in pre-clinical models, gene therapy approaches for the treatment of hemophilia are showing consistent evidence of long-term therapeutic benefit with the potential for a cure of the disease. In many respects, advances in the clinical care of the common inherited bleeding disorders represent a paradigm for the successful application of molecular science to enhance diagnosis and treatment.

The seminar will be followed by a drinks reception to celebrate Professor Anne Goodeve’s retirement.  If you would like to attend, please register your intention here.

Date: Wednesday 13th March 2019
Title: “Neutrophils in atherosclerosis – from physiology to intervention”
Speaker:  Professor Oliver Soehnlein, University of Munich.
Venue:  Lecture Theatre 3, F Floor Medical School.
Abstract:  Because of their rare detection in atherosclerotic lesions, the involvement of neutrophils in the pathophysiology of atherosclerosis has been largely neglected. However, over the past couple of years, studies have provided convincing evidence for the presence of neutrophils in atherosclerotic plaques and further revealed the causal contribution of neutrophils during various stages of atherosclerosis. In this presentation, I will describe mechanisms underlying hyperlipidemia-mediated neutrophilia and how neutrophils may enter atherosclerotic lesions. It also highlights possible mechanisms of neutrophil-driven atherogenesis and plaque destabilization. Finally, I will show how knowledge of this kind can help to generate innovative therapeutic strategies.